ECT

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of ECT

Quick Facts

Property Description
Active ingredient Etoricoxib
Form Oral Tablet (Film-Coated)
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use Symptomatic relief of pain and inflammation
Origin Synthetic organic compound

What Type of Medicine is ECT (Etoricoxib)?

The medicine ECT contains the active ingredient Etoricoxib and is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Specifically, Etoricoxib belongs to the specialized subclass of NSAIDs known as a coxib, a synthetic organic compound. This classification places it among drugs that specifically target inflammatory processes. Etoricoxib is a single-ingredient product designed for oral use, typically manufactured as a film-coated tablet. This substance is clinically recognized for its efficacy in controlling symptoms of chronic inflammation and pain.


How Does Etoricoxib Differ from Traditional Anti-Inflammatories?

Etoricoxib differentiates itself by its highly selective action on the Cyclooxygenase-2 (COX-2) enzyme, which is the primary driver of pain and inflammation. This means it is designed to block the enzyme responsible for producing Prostaglandins, the chemical messengers that signal pain and cause swelling. The drug's distinctive high COX-2 selectivity is a differentiating factor, as traditional NSAIDs often inhibit both COX-1 and COX-2. Etoricoxib is often positioned for patient groups requiring specific control over COX-2 activity, with its profile allowing for once-daily dosing, a key benefit for patient adherence.


What is the General Purpose of ECT?

The general purpose of Etoricoxib is to provide symptomatic relief by acting as a powerful anti-inflammatory and analgesic agent. Its primary general benefit is centered on controlling the body's response to inflammation and the associated discomfort. By reducing the Prostaglandins released via COX-2 inhibition, the medicine directly helps to alleviate swelling, reduce redness, and mitigate pain stemming from various inflammatory processes. The overall therapeutic goal is the effective management of pain and inflammation, such as the discomfort experienced during a typical flare-up of chronic joint issues. This specific action is consistent with its classification as a selective COX-2 inhibitor.

What side effects are possible with ECT?

Possible Side Effects and Safety Information

Official regulatory documents classify the possible adverse effects of Etoricoxib by frequency and the body system affected. The most frequently reported adverse reaction is abdominal pain, classified as Very Common in official prescribing information.


Adverse Reactions by Frequency

Frequency Category Examples of Documented Effects
Common (1 in 10 to 1 in 100) Oedema/fluid retention, headache, dizziness, hypertension, palpitations, nausea, flatulence, elevated liver enzymes (ALT/AST).
Rare (Less than 1 in 1,000) Hypersensitivity reactions including anaphylactic shock, and severe skin reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Serious Safety Concerns

The official safety profile highlights the risk of serious thrombotic arterial events, including Myocardial Infarction (MI) and Stroke. This risk is explicitly stated to increase with the dose and the duration of exposure.

Additionally, serious Gastrointestinal Complications, such as Perforations, Ulcers, or Bleedings (PUBs), some resulting in fatal outcomes, are documented. Patients are also noted to be at the highest risk for serious skin reactions early in the course of therapy.

Regulatory Safety Constraints

The medicine is officially contraindicated in patients with established Ischaemic Heart Disease, Peripheral Arterial Disease, and/or Cerebrovascular Disease. It is also restricted for use in patients with uncontrolled hypertension (persistently elevated above 140/90 mmHg) and in those with severe hepatic or renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents stipulate that it is mandatory to seek medical attention immediately upon any suspected overdose of Etoricoxib. This instruction is critical because specific acute signs or symptoms of toxicity are not formally listed in the labeling.


Documented Overdose Profile

Clinical data submitted to regulatory authorities, including studies of high single doses (up to 500 mg) and elevated daily doses (up to 150 mg for 21 days), indicate no significant toxicity resulted from this exposure. Therefore, the absence of acute symptoms should not delay the mandated emergency response.


Management and Supportive Care

Management of Etoricoxib overdose is strictly defined by the need for supportive measures, as the official documentation states no specific antidote is known. The required procedural steps include employing the usual supportive measures and performing procedures to remove unabsorbed material from the gastrointestinal tract.

Clinical monitoring must be employed, and supportive therapy instituted as required. A specific consideration noted is that Etoricoxib is not dialysable by haemodialysis, severely limiting the utility of this intervention for systemic clearance. The overall profile mandates immediate professional intervention based on exposure, not on symptom recognition.

Therapeutic Uses of ECT

What ECT Treats: Main Uses and Benefits

Etoricoxib is relevant for providing symptomatic relief across a range of clinical presentations characterized by significant discomfort and inflammation. It is generally applied in contexts where additional symptomatic support is needed to help patients cope more steadily with difficult episodes.


Key Therapeutic Domains

The medication is relevant in clinical settings marked by the heightened, fluctuating discomfort of long-term conditions like Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is also applied in contexts involving acute or disruptive symptom patterns, including the severe manifestations of Acute Gouty Arthritis, pain following Dental Surgery, and Primary Dysmenorrhea. It is commonly used to help with distressing manifestations such as persistent joint pain, swelling, and morning stiffness. It is relevant for managing symptoms that interfere with daily comfort.


Supportive Role in Discomfort

In situations requiring short-term assistance, Etoricoxib provides support that helps ease the overall symptom burden when symptoms create noticeable physiological strain. The medication may assist with easing the impact of symptoms on routine activities and supports general well-being during symptomatic phases.

Quick Fact: Supportive Role in Discomfort
Primary Symptom Focus: Symptoms related to physical discomfort, joint swelling, and stiffness.
Potential Benefit: May support day-to-day comfort and assist with maintaining functional stability.

Regulatory References

  1. HPRA Summary of Product Characteristics

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Electroconvulsive Therapy (ECT) — Official Regulatory Information

Electroconvulsive therapy (ECT) devices are regulated by the U.S. Food and Drug Administration (FDA), which defines eligibility based on patient age and condition.

Eligibility and Classification

The FDA classifies the use of ECT devices into two categories:

  • Class II (Lower Risk): This designation applies to patients age 13 years and older who are receiving treatment for catatonia or a severe major depressive episode (MDE) associated with Major Depressive Disorder or Bipolar Disorder, provided the patient is treatment-resistant or requires a rapid response. This is the standard, accepted use.
  • Class III (Higher Risk): This designation applies to all other intended uses, including treating conditions like schizophrenia, schizoaffective disorder, bipolar manic states, and any use in patients under 13 years of age. Class III uses require stricter regulatory review.

Contraindications and Restrictions

While no absolute contraindications are universally cited in core regulatory summaries, certain severe medical conditions are often considered relative contraindications or high-risk factors. These include elevated intracranial pressure with mass effect and pheochromocytoma. The decision to use ECT in the presence of risk factors requires careful medical consideration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or analgesic doses of Acetylsalicylic Acid (Aspirin) is officially contraindicated due to a further increased risk of serious gastrointestinal complications. Etoricoxib may be used with low-dose Aspirin for cardiovascular prophylaxis, but this combination still increases the overall risk of gastrointestinal adverse effects.

The interaction profile is defined by both pharmacokinetic and pharmacodynamic effects. Co-administration with Rifampin, a potent inducer of hepatic metabolism, is documented to significantly reduce Etoricoxib plasma exposure (AUC) by 65%. Conversely, Etoricoxib can increase the plasma concentration of certain co-administered drugs. For instance, an increase in Prothrombin Time International Normalized Ratio (INR) is associated with co-administration with Warfarin or other oral anticoagulants. Furthermore, Etoricoxib can increase the systemic exposure (AUC) of Ethinyl Estradiol (a component of oral contraceptives) by 50% to 60%.

Pharmacodynamic interactions include the potential for Etoricoxib to diminish the antihypertensive effect of ACE Inhibitors and ARBs, and to reduce the efficacy of Diuretics. The combination of these three classes is specifically noted to carry a risk of deterioration of renal function in elderly or volume-depleted patients. No clinically significant interaction is documented with Antacids. In patients with moderate hepatic impairment, Etoricoxib exposure is officially documented to increase by approximately 40%.

Mechanism of Action

How ECT Works

The mechanism of Electroconvulsive Therapy (ECT) involves initiating a precisely delivered, generalized seizure to induce a cascade of robust neurobiological effects that modulate activity within defined neural processes. This mechanism can be understood through two primary, interconnected domains:


Seizure-Induced Neurotransmitter Release and System Reset

ECT works by using a brief electrical stimulus to trigger a generalized seizure, which is the required physiological event. This immediate, intense neural synchronization causes a massive, but transient, alteration in central nervous system (CNS) signaling. This includes a widespread release and subsequent change in the sensitivity of receptors for key neurotransmitters like serotonin, dopamine, and GABA, resulting in altered activity within targeted neural pathways and impacting the trajectory of neural signaling.


Enhanced Neuroplasticity and Network Remodeling

Following the acute seizure, ECT engages mechanisms that influence long-term adaptive neural processes by significantly increasing the expression of neurotrophic factors (such as BDNF). This supports neuroplasticity, which is the ability of the brain to form new connections and structures. This biological adjustment is relevant in systems where targeted pathway adjustment is required, as it affects the functional remodeling and regulation of communication patterns between brain networks (functional connectivity), resulting in altered activity patterns across CNS pathways.

Dosage and Administration Information

Etoricoxib is administered solely via the oral route as a film-coated tablet. The fundamental principle guiding its use is to employ the lowest effective daily dose for the shortest duration possible. The medicine is designed for once-daily administration across all approved indications.


Standard Dosage and Frequency

The appropriate maximum dose is determined by the specific condition being addressed. For Osteoarthritis (OA), the recommended dose is typically 30 mg to a maximum of 60 mg once daily. For conditions like Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS), the maximum daily dose is 90 mg. Treatment for chronic conditions requires periodic re-evaluation to confirm the continued necessity of symptomatic relief.


Acute Use and Administration Context

Higher fixed doses are used for short-term acute symptomatic periods, such as 120 mg once daily for Acute Gouty Arthritis or 90 mg once daily for Postoperative Dental Surgery Pain. These high-dose regimens are subject to strict duration limits of up to 8 days or less, depending on the indication.

The tablets may be taken with or without food. Taking the medicine without food may accelerate the onset of its effect, which is a consideration when rapid relief is sought.


Population-Specific Limitations

No dose adjustment is generally necessary for older adults. However, use is prohibited in individuals under 16 years of age. Specific dose limitations are mandatory for patients with hepatic impairment. For moderate hepatic impairment (Child-Pugh 7–9), the maximum dose is restricted to 30 mg once daily.

Recent Clinical Evidence

ECT: Recent Clinical Evidence

The most authoritative evidence regarding Electroconvulsive Therapy (ECT) is derived from large-scale, systematic reviews and randomized controlled trials (RCTs). Research confirms its role as an important treatment option, particularly for severe, treatment-resistant, or psychotic depression, as well as for certain acute phases of bipolar disorder and catatonia.


Efficacy and Indications

Clinical data consistently demonstrate that ECT is among the most rapid and effective treatments available for severe depression, often showing a response rate higher than standard pharmacotherapy in highly refractory cases. Current research focuses on refining electrode placement and stimulus parameters to maximize therapeutic benefit while minimizing side effects.

  • Treatment-Resistant Depression: Multiple systematic reviews indicate that ECT remains the gold standard for achieving remission in patients who have failed to respond to multiple antidepressant medications.
  • Catatonia: Studies support ECT as a highly effective, often first-line intervention for both manic and depressive catatonia, frequently leading to rapid symptom resolution.

Optimization and Tolerability

Recent clinical studies emphasize the distinction between different ECT administration techniques to optimize tolerability. The two primary techniques compared in research are brief pulse (BP) stimulation and ultrabrief pulse (UBP) stimulation. Research has explored whether UBP ECT may offer comparable efficacy to BP ECT while resulting in less pronounced cognitive side effects, particularly relating to memory.

Technique Primary Research Focus
Brief Pulse (BP) Highest demonstrated efficacy in treatment-resistant cases.
Ultrabrief Pulse (UBP) Investigated for lower reported cognitive impact; efficacy may vary.

Overall, the consensus in the evidence is that ECT is an essential, high-impact therapeutic tool when administered in controlled clinical settings and under strict medical supervision.

Key Studies & References

  1. The National Institute for Health and Care Excellence (NICE) Guideline: Depression in adults: recognition and management (NG222), specific section on ECT

Frequently Asked Questions (FAQ)

Common questions about ECT (FAQ)


Q: Is ECT the same thing as electroshock therapy?

The procedure is formally known in regulatory and professional guidelines as Electroconvulsive Therapy (ECT). While electroshock therapy is a term used historically, ECT refers to the carefully controlled, modern medical procedure performed under general anesthesia.


Q: Does ECT involve a lot of electricity or does it hurt?

ECT does not hurt because it is performed while the patient is under general anesthesia and has been given a muscle relaxant. Regulatory protocols require these measures to ensure the patient is unconscious during the brief electrical stimulus and the resulting seizure.


Q: Do the effects of ECT last forever, or is it temporary?

Studies and official information indicate that ECT can lead to significant and rapid improvement in symptoms. However, continued treatment, such as prescribed antidepressants or other stabilizing medications, is generally advised following the ECT course to help maintain the improvement and manage the risk of symptom return.


Q: Can ECT be used during pregnancy?

ECT is generally considered as an option in severely ill pregnant patients. However, the presence of certain high-risk medical conditions in pregnancy is cited as a relative contraindication, meaning the decision is made based on individual clinical assessment.


Q: Do I need to be asleep for the ECT procedure?

Yes, ECT is always administered while the patient is asleep. The procedure is performed under general anesthesia and requires the use of a muscle relaxant to ensure patient safety and comfort throughout the brief treatment.


Q: What happens right before and after an ECT session?

Patients are typically required to fast (be nil per os or NPO) for a period before the procedure, similar to other surgeries involving anesthesia. Immediately after the procedure, common temporary effects may include headaches, muscle aches, tiredness, and a period of confusion.


Q: Why is ECT sometimes considered a controversial treatment?

Regulatory reviews and expert discussions acknowledge that ECT has historically been controversial. Much of the debate has centered on the severity of the associated risk of memory and cognitive impairment that may be experienced by some patients.


Q: Are headaches a common side effect of ECT?

Yes, authoritative sources note that headaches are a common adverse effect reported immediately following the ECT procedure. They are typically short-lived and manageable.


Q: What does ECT feel like during the treatment?

Due to the use of general anesthesia, the patient is unconscious during the treatment. Therefore, the patient does not feel the electrical stimulus or the resulting generalized seizure that is induced as part of the procedure.


Q: Is it possible for ECT to not work for someone?

While ECT is highly effective, especially for severe and treatment-resistant conditions, official professional reporting indicates that a small number of patients (around 1% in some audits) may show no change or a worsening of their condition at the end of the treatment course.


Q: How does ECT compare to transcranial magnetic stimulation (TMS)?

Authoritative sources indicate ECT has been shown to result in high response rates and is often rapid in achieving remission. This information is considered when comparing it to other neuromodulation treatments such as Transcranial Magnetic Stimulation (rTMS).


Q: Can ECT be given to elderly patients?

Studies indicate that ECT may be considered as a treatment option in severely ill elderly patients when medically necessary. The decision to proceed is based on a careful risk-benefit analysis by the medical team.


Q: Does ECT require hospitalization?

ECT may be performed in an inpatient or an outpatient setting. Official reviews show that the procedure is often delivered on an outpatient basis, depending on the patient's condition, the severity of their illness, and local clinic protocols.


Q: What is the general success rate described in studies for ECT?

Clinical studies consistently report high response and remission rates for ECT in patients with severe mental illness. This indicates that a large percentage of patients experience significant improvement.


Q: Why is anesthesia required for every ECT session?

Anesthesia is mandatory because the goal of ECT is to initiate a generalized seizure. It is administered along with a muscle relaxant to protect the patient by preventing severe muscle contractions during the seizure.


Q: Does ECT cause permanent brain damage?

According to regulatory commentary and medical literature reviews, there is no evidence of brain damage associated with properly administered ECT in adolescents or adults. The procedure is designed to induce changes in central nervous system activity.


Q: What is the typical time commitment for an ECT course?

The typical course of ECT involves multiple administrations, usually given two or three times per week. The total commitment continues until the patient has achieved a clinical response or remission, which can vary widely.


Q: Is ECT painful after the session is over?

While the procedure itself is painless due to anesthesia, patients may report temporary physical discomfort afterward. Common reports include experiencing a headache or muscle and jaw aching immediately after the session.


Q: Why do doctors use muscle relaxers during ECT?

Doctors administer a muscle relaxant (like succinylcholine) during the procedure. This essential step is taken to reduce or completely prevent the tonic-clonic contractions that are normally associated with a generalized seizure, ensuring patient safety.


Q: Can ECT affect my ability to learn new things?

Regulatory documents list cognitive and memory impairment as an identified risk. This can sometimes affect the ability to retain new information, a type of memory difficulty that regulatory documents describe as a risk.


Q: Why are people often confused right after an ECT session?

Confusion is one of the most common and expected temporary adverse effects experienced immediately following ECT treatment. It usually wears off rapidly as the effects of the anesthesia subside.


Q: What is the device used for ECT called?

According to FDA and other regulatory reports, the official name for the equipment used in the procedure is an Electroconvulsive Therapy Device.


Q: Does ECT cause noticeable changes in brain scans?

The mechanism involves initiating robust neurobiological effects that influence central nervous system activity and altered communication patterns between brain networks. This is the goal of the treatment.


Q: What official documents describe ECT's safety profile?

The FDA's classification orders for the device and the agency's review of safety and effectiveness are key regulatory documents. These agency reviews describe the identified risks and specify the special controls required for safe use.


Q: Is ECT still used frequently today?

Yes, ECT is still a current treatment option in many countries. For example, estimates indicate that tens of thousands of ECT treatments are delivered annually in countries like Canada.


Q: Why is ECT an option when talking treatments haven't helped?

Studies show that in cases of severe illness where non-biological treatments have not been successful, ECT may be considered due to its high response rates in refractory cases.

How should ECT be stored and disposed of?

Storage and Disposal of Etoricoxib

The storage and disposal of Etoricoxib tablets must strictly adhere to the requirements documented in official regulatory labeling to maintain product stability and ensure public safety.


Official Storage Requirements

Condition Requirement
Temperature Store at a temperature not exceeding 30°C.
Protection Keep in the original blister pack to protect the tablets from moisture.
Child Safety Keep the medicine out of the sight and reach of children.

Official Disposal Rules

To prevent environmental contamination, unused or expired Etoricoxib must not be thrown into household waste or disposed of via wastewater. Disposal must follow the specific procedures for pharmaceutical waste as defined by local requirements and health authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of ECT found in:

A-Z Index: